GlassScriptPhysician profile
Ellen Michelle Depoy
NPI 1992230726
$2,145.31
in general payments reported to CMS, 2019-2025
14 companies · $465 in 2025
The $465 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $706 · 2023: $614 · 2024: $360 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,438.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $875.40 | 2022-2025 | Ubrelvy, Botox, Qulipta |
| Impel Pharmaceuticals INC. | $355.21 | 2022-2023 | Trudhesa |
| Lilly USA, LLC | $266.66 | 2022 | |
| Lundbeck LLC | $152.08 | 2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $128.51 | 2022 | |
| Alexion Pharmaceuticals, INC. | $87.91 | 2023-2024 | Ultomiris, Soliris |
| Amneal Pharmaceuticals LLC | $59.02 | 2023-2024 | Crexont, Lyvispah |
| Emd Serono, INC. | $56.82 | 2023 | Mavenclad |
| Merz Pharmaceuticals, LLC | $46.72 | 2023 | Xeomin |
| Pfizer INC. | $46.46 | 2024-2025 | |
| Genentech USA, INC. | $21.65 | 2024 | Enspryng, Ocrevus |
| Biogen, INC. | $19.38 | 2023 | Vumerity |
| Jazz Pharmaceuticals INC. | $15.82 | 2023 | Epidiolex |
| Neurelis, INC. | $13.67 | 2023 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Depoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.